Companies: 10,795·Total market cap: $144.5T
ImmuPharma plc

ImmuPharma plc

IMMPFOTCHealthcare
$0.09
+$0.00(+0.00%)
Market Cap$28339256
P/E Ratio
52W High$0.085
52W Low$0.08

ImmuPharma plc (IMMPF) Market Cap & Net Worth

Live market cap, enterprise value, and global rank — multi-year chart and annual table below.

immpf · market cap & enterprise value · FMP · as of Apr 19, 2022

Core market cap & key metrics

As of Apr 19, 2022, ImmuPharma plc (IMMPF) has a market cap — also referred to as its net worth or valuation — of $28,339,256, making it one of the top most valuable companies globally. Market Cap = $0.09 × shares outstanding.

Market Cap (Net Worth)$28,339,256immpf market cap 2026
Enterprise ValuemktCap + debt − cash
1-Year Changevs one year ago
Global Rankinglargest company by mkt cap
All-Time High$0immpf highest market cap ever
Stock Price$0.09OTC · Apr 19, 2022
How is Market Cap calculated?Market Cap = Stock Price × Shares Outstanding

About Market Cap, Net Worth & Valuation

ImmuPharma plc (IMMPF) has a market cap — also referred to as its net worth or valuation — of $28,339,256 as of Apr 19, 2022, making it the #0 most valuable company globally. Market Cap = Stock Price × Shares Outstanding.

ImmuPharma plc reached its all-time high market cap of $0 on —. Comparing the ImmuPharma plc market cap history illustrates one of the most extraordinary corporate growth stories.

Investors frequently compare ImmuPharma plc net worth vs peers and ask how ImmuPharma plc valuation compares to other countries. Its market cap reflects continued investor confidence.

Data: FMP · year-end market cap · not investment advice

Frequently Asked Questions

IMMPF market cap · 6 questions

ImmuPharma plc's net worth — measured as market capitalization — is $28,339,256 as of Apr 19, 2022. It ranks #0 globally. Market Cap = $$0.09 (price) × shares outstanding.

IMMPF net worth 2026market cap vs book valuelargest companies by market cap
Data: Financial Modeling Prep · Market cap updates daily · For informational purposes only, not investment advice.